DDInter1652 DDInter1045
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019.
Levamlodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Levamlodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Levamlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tyropanoic acid
Levamlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Levamlodipine {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Levamlodipine {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Levamlodipine may lead to a major life threatening interaction when taken with Enzalutamide
Levamlodipine may lead to a major life threatening interaction when taken with Apalutamide